Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 tri­al; No­vavax de­lays PhI­II tri­al in US, with PhII da­ta com­ing Fri­day

With big ques­tions still hang­ing over the fate of the vac­cines and drugs now in late-stage de­vel­op­ment for Covid-19, Boehringer In­gel­heim is pulling one of its ear­ly-stage drugs in­to a Phase II tri­al to see if it can help some of the most se­vere­ly af­flict­ed pa­tients.

Put through a safe­ty study last year, re­searchers have been in­trigued by the po­ten­tial of BI 764198 — a TR­PC6 in­hibitor — as a treat­ment for acute res­pi­ra­to­ry dis­tress syn­drome (ARDS), which can cause im­mense dam­age and death for pa­tients ex­posed to the virus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER